InVentiv Health

The story of inVentiv Health begins not with a single founder, but as a spin-off from Snyder Communications in 1999, first named Ventiv Health. This entity was built to provide outsourced services to the pharmaceutical industry, a crucial link in the chain from laboratory to patient. Early on, the company established its core business in helping drug companies with the critical phases of clinical development and commercialization. A key moment arrived in 2010 when private equity firm Thomas H. Lee Partners acquired the company, taking it private in a deal valued at approximately $1.1 billion. This move injected new capital and strategic direction. The company continued to grow through acquisitions, expanding its capabilities across clinical research and commercial services. By 2016, inVentiv was a major player, involved in the development or commercialization of a high percentage of FDA-approved drugs. The company filed for an IPO in 2016 to manage its debt, but later canceled the offering when private equity firm Advent International took an equal stake alongside Thomas H. Lee Partners. The most significant event in its journey occurred in 2017 when inVentiv Health announced a merger of equals with a competitor, INC Research. This all-stock transaction created a combined entity valued at approximately $7.4 billion, positioning it as one of the largest biopharmaceutical outsourcing providers globally. This new powerhouse was rebranded as Syneos Health, symbolizing the synchronization of clinical and commercial services to accelerate the delivery of new therapies.